Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended March 2025, Hologic (HOLX) reported revenue of $1.01 billion, down 1.2% over the same period last year. EPS came in at $1.03, compared to $1.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1 billion, representing a surprise of +0.34%. The company delivered an EPS surprise of +0.98%, with the consensus EPS estimate being $1.02.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Hologic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Diagnostics- Cytology and perinatal: $118.50 million compared to the $119.94 million average estimate based on three analysts. The reported number represents a change of -1.7% year over year. Revenues- Diagnostics- Molecular diagnostics: $326 million compared to the $328.58 million average estimate based on three analysts. The reported number represents a change of +1% year over year. Revenues- Diagnostics- Blood screening: $9.10 million versus the three-analyst average estimate of $4.99 million. The reported number represents a year-over-year change of +31.9%. Revenues- Breast health- Breast imaging: $271.90 million compared to the $282.58 million average estimate based on three analysts. The reported number represents a change of -11.4% year over year. Revenues- Skeletal health: $33 million compared to the $18 million average estimate based on three analysts. The reported number represents a change of +21.8% year over year. Revenues- Total Breast health: $356.20 million compared to the $369.50 million average estimate based on three analysts. The reported number represents a change of -7.4% year over year. Revenues- Total Diagnostics: $453.60 million versus the three-analyst average estimate of $453.52 million. The reported number represents a year-over-year change of +0.8%. Revenues- GYN surgical: $162.50 million versus $161.11 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change. Revenues- Breast health- Interventional breast solutions: $84.30 million versus the three-analyst average estimate of $86.91 million. The reported number represents a year-over-year change of +8.2%. View all Key Company Metrics for Hologic here>>>Shares of Hologic have returned -3.9% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks